Navigation Links
Drug that targets vasculature growth attacks aggressive thyroid cancer
Date:5/15/2009

ORLANDO - A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

At the annual meeting of the American Society of Clinical Oncology (ASCO), Mayo investigators report that cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank.

The patient responses seen to date are promising, the researchers say, because all patients had fast-growing cancers that had spread to their lungs, with half involving lymph nodes and 39 percent also involving bones.

"The benefits were striking in many patients to a degree we have not previously seen in thyroid cancer in response to other therapies, including the standard treatment of radioiodine," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial funded by the National Cancer Institute. Most of the patients treated were enrolled at the Mayo Clinic campuses in Minnesota and Florida.

Approximately one-third of patients achieved sustained and dramatic benefit from pazopanib, while another one-third experienced stabilization of their cancer or some tumor shrinkage. The remaining one-third of patients did not benefit from the drug. The agent was also well tolerated by the majority of patients, Dr. Bible adds.

What is not yet known, however, is the drug's effect on overall survival. "We need more time to establish that definitively," says Dr. Bible. "The trial has been going on for just over a year, and some of our patients are still maintaining a response, while others have not been in the study long enough for us to confirm duration of response." He notes that of the 37 original trial participants, two have died one from cancer progression and another from other causes.

The National Cancer Institute estimated that 37,340 new cases of thyroid cancer would be diagnosed in 2008, with 1,590 deaths from the cancer. The cancer is much more common in women; it is the seventh most common cancer in women in the U.S. The occurrence of thyroid cancer has recently been rising.

Most thyroid cancers are of two major "differentiated" types papillary thyroid cancer (the most common, accounting for 75 percent of cases) and follicular thyroid cancer (15 percent).

Fortunately, most patients with thyroid cancer respond well to surgery and to follow-up treatment with radioiodine; even if the cancer recurs and spreads, the disease progresses slowly in most patients, Dr. Bible says. "Many patients do well for a long time without the need of additional therapy," he says. However, about 5 percent of these patients experience rapidly progressing life-threatening disease that is insensitive to radioiodine and other treatment approaches. "Until only recently, we have not had any effective therapies for such patients."

Pazopanib is an experimental agent that is also being studied in advanced kidney, ovarian and other cancers. The drug, administered in pill form, targets proteins involved in angiogenesis, the growth of new blood vessels that has a critical role in the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-kit and Ret.

Mayo investigators are also leading clinical trials to test pazopanib in two other thyroid cancer subtypes -medullary, which does not respond to radioiodine, and anaplastic, the most aggressive subtype.

Dr. Bible says plans are also under way to test pazopanib in a larger, controlled and randomized clinical trial of patients with advanced differentiated thyroid cancer. Researchers want to more accurately assess benefits and risks.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New Federal Legislation Targets Toxic Chemicals in Baby Bath Products
2. Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets
3. AMDL, Inc. Reports 2008 Year End Financial Results and Fiscal Year 2009 Financial Targets
4. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
5. Stimulus Spending Targets Modernization of the Nation's Research Infrastructure
6. Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work
7. Scientists Discover New Drug Targets for Crohns Disease
8. New bubble targets only cancer cells
9. OHSU vaccine research targets HIV in the slower, early stage of infection
10. Nanoparticle smart bomb targets drug delivery to cancer cells
11. NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology: